June 15, 2023
3 min watch
Save
VIDEO: COMMANDS study shows luspatercept as option for low-risk myelodysplastic syndrome
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Eunice Wang, MD, discussed the results of the phase 3 COMMANDS study, pertaining to low-risk myelodysplastic syndrome, presented at ASCO Annual Meeting.
Wang, chief of the leukemia service at Roswell Park Comprehensive Cancer Center, highlighted the study, which presented data suggesting that luspatercept (Reblozyl; Celgene, Bristol Myers Squibb) could improve quality of life in place of or addition to erythropoiesis-stimulating agent therapy.
“We’re looking forward to having this as another agent in our armamentarium for lower-risk patients,” Wang said.
Published by:
Sources/Disclosures
Collapse
Disclosures:
Wang reports consulting, advising and speaking for AbbVie, Amgen, Astellas, Bristol Myers Squibb, CTI Biopharm, Daiichi Sankyo, Gilead, GSK, Janssen, Jazz Pharmaceuticals, Kite Pharma, Kura Oncology, Novartis, Pfizer, PharmaEssentia, Rigel, Sellas, Stemline and Sumitomo Pharma.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.